Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Acquisition expands high-value medical platform
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Subscribe To Our Newsletter & Stay Updated